Targeted in vivo delivery of EGFR siRNA inhibits ovarian cancer growth and enhances drug sensitivity.
A functionalized nanohydrogel siRNA delivery system and a mouse model of serous ovarian cancer were used to test predictions from previous cell line studies that knockdown of EGFR (epidermal growth factor receptor) may be of clinical significance in the treatment of epithelial tumors especially with respect to the enhancement of platinum based therapies. Our results support these predictions and suggest that targeted delivery of EGFR siRNA may be an effective strategy for the treatment of ovarian and other epithelial tumors associated with elevated levels of EGFR and especially those demonstrating resistance to platinum-based therapies.
Integrated Cancer Research Center, 315 Ferst Drive, Atlanta, GA 30332, USA.|School of Biological Sciences, 315 Ferst Drive, Atlanta, GA 30332, USA.|Petit Institute for Bioengineering and BioScience, Georgia Institute of Technology, 315 Ferst Drive, Atlanta, GA 30332, USA.
Minati
M
Satpathy
Integrated Cancer Research Center, 315 Ferst Drive, Atlanta, GA 30332, USA.|School of Biological Sciences, 315 Ferst Drive, Atlanta, GA 30332, USA.|Petit Institute for Bioengineering and BioScience, Georgia Institute of Technology, 315 Ferst Drive, Atlanta, GA 30332, USA.
Roman
R
Mezencev
Integrated Cancer Research Center, 315 Ferst Drive, Atlanta, GA 30332, USA.|School of Biological Sciences, 315 Ferst Drive, Atlanta, GA 30332, USA.|Petit Institute for Bioengineering and BioScience, Georgia Institute of Technology, 315 Ferst Drive, Atlanta, GA 30332, USA.
Lijuan
L
Wang
Integrated Cancer Research Center, 315 Ferst Drive, Atlanta, GA 30332, USA.|School of Biological Sciences, 315 Ferst Drive, Atlanta, GA 30332, USA.|Petit Institute for Bioengineering and BioScience, Georgia Institute of Technology, 315 Ferst Drive, Atlanta, GA 30332, USA.
John F
JF
McDonald
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D051379:Mice; D016513:Mice, SCID; D009944:Organoplatinum Compounds / Q000494:pharmacology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics; D034622:RNA Interference / Q000187:drug effects; D034741:RNA, Small Interfering / Q000235:genetics
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D034741:RNA, Small Interfering; C541485:EGFR protein, mouse; D066246:ErbB Receptors